Comparative efficacy and acceptability of pharmacological interventions for postpartum depression: a systematic review and network meta-analysis.
Yao Xiao, Ping Xie, Danlei Li et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis evaluated the efficacy and acceptability of pharmacological treatments for postpartum depression (PPD) across 18 trials involving 1722 participants. The analysis found that saffron (SMD -1.07), fluoxetine (SMD -0.95), and esketamine (SMD -0.63) significantly improved depressive symptoms compared to placebo. Brexanolone was the only treatment showing significant remission improvement.
Key findings
- Saffron showed a significant reduction in depressive symptoms (SMD -1.07, 95% CI -1.52 to -0.61) compared to placebo.
- Brexanolone was the only intervention with a statistically significant improvement in remission.
- Zuranolone was associated with an increased incidence of adverse events.
- Fluoxetine and saffron had higher response rates, though estimates were imprecise.
Why it matters
Understanding the comparative efficacy and acceptability of various pharmacological treatments for postpartum depression is crucial for clinicians to make informed treatment decisions, especially given the potential for adverse effects and varying response rates among different medications.
What to keep in mind
The evidence is limited by sparse networks, low-to-moderate certainty, and imprecision in some estimates.